相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients
Thomas Mueller et al.
CELLS (2022)
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Michael J Soileau et al.
LANCET NEUROLOGY (2022)
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
Filip Bergquist et al.
NEUROLOGY (2022)
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
Joaquim J. Ferreira et al.
MOVEMENT DISORDERS (2022)
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary A Report of the AAN Guideline Subcommittee
Tamara Pringsheim et al.
NEUROLOGY (2021)
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study
Nir Giladi et al.
PARKINSONISM & RELATED DISORDERS (2021)
Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in Clinical Practice
Mezin Othman et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone
Peter Jenner et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study
Werner Poewe et al.
MOVEMENT DISORDERS (2021)
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
Eric Freire-Alvarez et al.
MOVEMENT DISORDERS (2021)
Personalized Medicine Approach in Treating Parkinson's Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
Helga Maria Gretarsdottir et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Dyskinesia Matters: But Not as Much as It Used to
K. Ray Chaudhuri et al.
MOVEMENT DISORDERS (2020)
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa
Roberto Cilia et al.
BRAIN (2020)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebocontrolled phase 3 trial (vol 18, pg 145, 2019)
P. A. LeWitt et al.
LANCET NEUROLOGY (2019)
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease
C. V. M. Verschuur et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease
Peter A. LeWitt et al.
PARKINSONISM & RELATED DISORDERS (2019)
Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations
Nishit B. Modi et al.
CLINICAL NEUROPHARMACOLOGY (2019)
Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
Nishit B. Modi et al.
CLINICAL NEUROPHARMACOLOGY (2019)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Peter A. LeWitt et al.
LANCET NEUROLOGY (2019)
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study
Marina Senek et al.
MOVEMENT DISORDERS (2017)
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Emanuele Cereda et al.
JOURNAL OF NEUROLOGY (2017)
ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease
Angelo Antonini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Valerie Voon et al.
LANCET NEUROLOGY (2017)
Impulse Control Disorders in Advanced Parkinson's Disease With Dyskinesia: The ALTHEA Study
Roberta Biundo et al.
MOVEMENT DISORDERS (2017)
Personalized Medicine in Parkinson's Disease: Time to Be Precise
Nataliya Titova et al.
MOVEMENT DISORDERS (2017)
Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff
Heiko Braak et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
Chava Peretz et al.
CLINICAL NEUROPHARMACOLOGY (2016)
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
Thomas Mueller
DRUGS (2015)
Trends in inpatient antiparkinson drug use in the USA, 2001-2012
James A. G. Crispo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma et al.
MOVEMENT DISORDERS (2015)
MDS research criteria for prodromal Parkinson's disease
Daniela Berg et al.
MOVEMENT DISORDERS (2015)
Gastroretentive Carbidopa/Levodopa, DM-1992, for the Treatment of Advanced Parkinson's Disease
Leo Verhagen Metman et al.
MOVEMENT DISORDERS (2015)
Novel Formulations and Modes of Delivery of Levodopa
Werner Poewe et al.
MOVEMENT DISORDERS (2015)
Clinical Spectrum of Impulse Control Disorders in Parkinson's Disease
Daniel Weintraub et al.
MOVEMENT DISORDERS (2015)
Levodopa Therapy for Parkinson's Disease: Pharmacokinetics and Pharmacodynamics
Peter A. LeWitt
MOVEMENT DISORDERS (2015)
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial
Eduardo Tolosa et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised
Richard Gray et al.
LANCET (2014)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson's Disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2014)
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor
M. J. Bonifacio et al.
NEUROPHARMACOLOGY (2014)
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients
Fabrizio Stocchi et al.
PARKINSONISM & RELATED DISORDERS (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers
D. Nyholm et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of CarbidopaLevodopa, and Immediate-Release CarbidopaLevodopa in Patients With Advanced Parkinson's Disease
Zhongping Mao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2013)
The current and projected economic burden of Parkinson's disease in the United States
Stacey L. Kowal et al.
MOVEMENT DISORDERS (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations
Kimmo Ingman et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial
D. Nyholm et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease
Wolfgang H. Jost et al.
BASAL GANGLIA (2012)
Should Treatment for Parkinson's Disease Start Immediately on Diagnosis or Delayed until Functional Disability Develops?
Carl E. Clarke et al.
MOVEMENT DISORDERS (2011)
Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications
Elise Anderson et al.
PARKINSONISM & RELATED DISORDERS (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson Disease
Matthew A. Brodsky et al.
ARCHIVES OF NEUROLOGY (2010)
Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study
Roberta Zangaglia et al.
CLINICAL NEUROPHARMACOLOGY (2010)
When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease?
Fabrizio Stocchi et al.
EUROPEAN NEUROLOGY (2010)
Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease
Ray L. Watts et al.
MOVEMENT DISORDERS (2010)
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
Mikko Kuoppamaki et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
Angelo Antonini et al.
LANCET NEUROLOGY (2009)
Adherence to Antiparkinson Medication in a Multicenter European Study
Donald Grosset et al.
MOVEMENT DISORDERS (2009)
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Robert Caslake et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
An expert opinion on safinamide in Parkinson's disease
Marco Onofrj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
R. Katzenschlager et al.
NEUROLOGY (2008)
A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis
D. Grosset et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
The progression of Parkinson disease - A hypothesis
Anthony E. Lang
NEUROLOGY (2007)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease
Peter Riederer et al.
PARKINSONISM & RELATED DISORDERS (2007)
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
Robert A. Hauser et al.
ARCHIVES OF NEUROLOGY (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
AHV Schapira et al.
ANNALS OF NEUROLOGY (2006)
Treatment should not be initiated too soon in Parkinson's disease
MJ Aminoff
ANNALS OF NEUROLOGY (2006)
Suboptimal medication adherence in Parkinson's disease
KA Grosset et al.
MOVEMENT DISORDERS (2005)
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease - A clinical and pharmacokinetic study
F Stocchi et al.
ARCHIVES OF NEUROLOGY (2005)
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
D Nyholm et al.
NEUROLOGY (2005)
Levodopa in the treatment of Parkinson's disease: Current controversies
CW Olanow et al.
MOVEMENT DISORDERS (2004)
Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned rat
M Gerlach et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
DJ Brooks et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
Ten-year follow-up of three different initial treatments in de-novo PD - A randomized trial
AJ Lees et al.
NEUROLOGY (2001)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
